{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T07:00:13Z","timestamp":1793170813896,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:00:00Z","timestamp":1764979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Orthop Surg Traumatol"],"DOI":"10.1007\/s00590-025-04604-x","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T06:47:06Z","timestamp":1765003626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["GLP-1 receptor agonist utilization is associated with a low risk of Anesthesia-related complications prior to total joint arthroplasty"],"prefix":"10.1007","volume":"36","author":[{"given":"Ryan","family":"C. Palmer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S.","family":"Telang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie M.","family":"Kistler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory K.","family":"Mayfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gligor","family":"Gucev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay R.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathanael D.","family":"Heckmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,6]]},"reference":[{"key":"4604_CR1","doi-asserted-by":"publisher","unstructured":"Emmerich SD, Fryar CD, Stierman B, Ogden CL (2024) Obesity and severe obesity prevalence in adults: united States, August 2021-August 2023. https:\/\/doi.org\/10.15620\/cdc\/159281. NCHS Data Brief","DOI":"10.15620\/cdc\/159281"},{"key":"4604_CR2","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.2106\/JBJS.17.01617","volume":"100","author":"M Sloan","year":"2018","unstructured":"Sloan M, Premkumar A, Sheth NP (2018) Projected volume of primary total joint arthroplasty in the U.S., 2014 to 2030. J Bone Joint Surg Am 100:1455\u20131460","journal-title":"J Bone Joint Surg Am"},{"key":"4604_CR3","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.arth.2013.02.011","volume":"28","author":"Workgroup of the American Association of Hip and Knee Surgeons Evidence Based Committee","year":"2013","unstructured":"Workgroup of the American Association of Hip and Knee Surgeons Evidence Based Committee (2013) Obesity and total joint arthroplasty: a literature based review. J Arthroplasty 28:714\u2013721","journal-title":"J Arthroplasty"},{"key":"4604_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211","author":"SH Han","year":"2023","unstructured":"Han SH, Safeek R, Ockerman K et al (2023) Public interest in the Off-Label use of Glucagon-Like peptide 1 agonists (Ozempic) for cosmetic weight loss: A Google trends analysis. Aesthet Surg J. https:\/\/doi.org\/10.1093\/asj\/sjad211","journal-title":"Aesthet Surg J"},{"key":"4604_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","volume":"118","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ruan B, Jiang H et al (2023) The Weight-loss effect of GLP-1RAs Glucagon-Like Peptide-1 receptor agonists in Non-diabetic individuals with overweight or obesity: A systematic review with Meta-Analysis and trial sequential analysis of randomized controlled trials. Am J Clin Nutr 118:614\u2013626","journal-title":"Am J Clin Nutr"},{"key":"4604_CR6","unstructured":"Zepbound\u2122 (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity. In: Eli Lilly and Company. https:\/\/investor.lilly.com\/news-releases\/news-release-details\/zepboundtm-tirzepatide-now-available-us-pharmacies-adults-living. Accessed 5 Dec 2023"},{"key":"4604_CR7","unstructured":"Office of the Commissioner (2021) FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014. In: U.S. Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treatment-chronic-weight-management-first-2014. Accessed 5 Dec 2023"},{"key":"4604_CR8","unstructured":"Center for Drug Evaluation, Research (2021) FDA approves weight management drug for patients aged 12 and older. In: U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-weight-management-drug-patients-aged-12-and-older. Accessed 14 Dec 2023"},{"key":"4604_CR9","unstructured":"Office of the Commissioner (2023) FDA Approves New Medication for Chronic Weight Management. In: U.S. Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-medication-chronic-weight-management. Accessed 14 Dec 2023"},{"key":"4604_CR10","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002","journal-title":"N Engl J Med"},{"key":"4604_CR11","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205\u2013216","journal-title":"N Engl J Med"},{"key":"4604_CR12","doi-asserted-by":"crossref","unstructured":"Gratzl S, Cartwright BMG, Rodriguez PJ et al (2025) Monitoring report: GLP-1 RA prescribing trends - March 2025 data. medRxiv 2025.03.06.25323524","DOI":"10.1101\/2025.03.06.25323524"},{"key":"4604_CR13","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","volume":"70","author":"SR Klein","year":"2023","unstructured":"Klein SR, Hobai IA (2023) Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth 70:1394\u20131396","journal-title":"Can J Anaesth"},{"key":"4604_CR14","doi-asserted-by":"publisher","unstructured":"Kittner SL, Talbott AL, Vishneski SR et al (2023) Retained gastric contents after adequate fasting associated with GLP-1 receptor agonist use: A report of 3 cases. https:\/\/doi.org\/10.2106\/JBJS.CC.23.00506. JBJS Case Connect 13.","DOI":"10.2106\/JBJS.CC.23.00506"},{"key":"4604_CR15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","volume":"11","author":"TD Filippatos","year":"2014","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS (2014) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 11:202\u2013230","journal-title":"Rev Diabet Stud"},{"key":"4604_CR16","doi-asserted-by":"publisher","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Chen J, Wang L et al (2022) Association between different GLP-1 receptor agonists and Gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne) 13:1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4604_CR17","unstructured":"American society of anesthesiologists consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. https:\/\/www.asahq.org\/about-asa\/newsroom\/news-releases\/2023\/06\/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative. Accessed 18 Dec 2023"},{"key":"4604_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2133\/dmpk.16.364","volume":"16","author":"C Naito","year":"2001","unstructured":"Naito C (2001) How foreign clinical data package can be utilized to get a Speedy approval of the new Drug. The bridging study strategy. Drug Metab Pharmacokinet 16:364\u2013369","journal-title":"Drug Metab Pharmacokinet"},{"key":"4604_CR19","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1016\/j.arth.2024.05.079","volume":"39","author":"A Buddhiraju","year":"2024","unstructured":"Buddhiraju A, Kagabo W, Khanuja HS et al (2024) Decreased risk of readmission and complications with preoperative GLP-1 analog use in patients undergoing primary total joint arthroplasty. J Arthroplasty 39:2911\u20132915e1","journal-title":"J Arthroplasty"},{"key":"4604_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/j.arth.2024.10.099","volume":"40","author":"KY Heo","year":"2025","unstructured":"Heo KY, Goel RK, Woltemath A et al (2025) Glucagon-like peptide-1 receptor agonist use is not associated with increased complications after total hip arthroplasty in patients who have type 2 diabetes. J Arthroplasty 40:1413\u20131418e1","journal-title":"J Arthroplasty"},{"key":"4604_CR21","doi-asserted-by":"crossref","unstructured":"Kim BI, Khilnani TK, LaValva SM et al (2025) Utilization of glucagon-like peptide-1 receptor agonist at the time of total hip arthroplasty for patients who have morbid obesity. J Arthroplasty 40:S259\u2013S264.e1","DOI":"10.1016\/j.arth.2024.12.008"},{"key":"4604_CR22","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.arth.2025.03.012","volume":"40","author":"JT Verhey","year":"2025","unstructured":"Verhey JT, Austin RP, Tarabichi S et al (2025) GLP-1 agonists for weight loss: do they increase complications in non-diabetic patients undergoing primary total hip arthroplasty? J Arthroplasty 40:S101\u2013S107","journal-title":"J Arthroplasty"},{"key":"4604_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.arth.2025.07.015","author":"V Lee","year":"2025","unstructured":"Lee V, Durkee SM, Ponce BA et al (2025) Impact of glucagon-like peptide-1 receptor agonists on postoperative outcomes in arthroplasty: A systematic review. J Arthroplasty. https:\/\/doi.org\/10.1016\/j.arth.2025.07.015","journal-title":"J Arthroplasty"},{"key":"4604_CR24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2106\/JBJS.24.00468","volume":"107","author":"BI Kim","year":"2025","unstructured":"Kim BI, LaValva SM, Parks ML et al (2025) Glucagon-like peptide-1 receptor agonists decrease medical and surgical complications in morbidly obese patients undergoing primary TKA. J Bone Joint Surg Am 107:348\u2013355","journal-title":"J Bone Joint Surg Am"},{"key":"4604_CR25","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.2106\/JBJS.23.00146","volume":"105","author":"KC Liu","year":"2023","unstructured":"Liu KC, Piple AS, Richardson MK et al (2023) Increased risk of venous thromboembolism in patients with postoperative anemia after total joint arthroplasty: are transfusions to blame? are transfusions to blame? J Bone Joint Surg Am 105:1354\u20131361","journal-title":"J Bone Joint Surg Am"},{"key":"4604_CR26","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3390\/jcm13113046","volume":"13","author":"K-H Shin","year":"2024","unstructured":"Shin K-H, Kim J-H, Han S-B (2024) Greater risk of periprosthetic joint infection associated with prolonged operative time in primary total knee arthroplasty: Meta-analysis of 427,361 patients. J Clin Med 13:3046","journal-title":"J Clin Med"},{"key":"4604_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.diabet.2017.05.009","volume":"43","author":"Y Nakatani","year":"2017","unstructured":"Nakatani Y, Maeda M, Matsumura M et al (2017) Effect of GLP-1 receptor agonist on Gastrointestinal tract motility and residue rates as evaluated by capsule endoscopy. Diabetes Metab 43:430\u2013437","journal-title":"Diabetes Metab"},{"key":"4604_CR28","doi-asserted-by":"publisher","first-page":"111091","DOI":"10.1016\/j.jclinane.2023.111091","volume":"87","author":"SQ Silveira","year":"2023","unstructured":"Silveira SQ, da Silva LM, de Campos Vieira Abib A et al (2023) Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy. J Clin Anesth 87:111091","journal-title":"J Clin Anesth"},{"key":"4604_CR29","unstructured":"Beam WB, Hunter Guevara LR Are serious anesthesia risks of semaglutide and other GLP-1 agonists under-recognized? Case reports of retained solid gastric contents in patients \u2026 Anesthesia Patient Safety Foundation (APSF"},{"key":"4604_CR30","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1177\/10600280211055804","volume":"56","author":"JE Stark","year":"2022","unstructured":"Stark JE, Cole JL, Ghazarian RN, Klass MJ (2022) Impact of Glucagon-Like Peptide-1 receptor agonists (GLP-1RA) on food content during Esophagogastroduodenoscopy (EGD). Ann Pharmacother 56:922\u2013926","journal-title":"Ann Pharmacother"},{"key":"4604_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/dom.14551","volume":"24","author":"S Wharton","year":"2022","unstructured":"Wharton S, Calanna S, Davies M et al (2022) Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between Gastrointestinal adverse events and weight loss. Diabetes Obes Metab 24:94\u2013105","journal-title":"Diabetes Obes Metab"},{"key":"4604_CR32","doi-asserted-by":"publisher","unstructured":"Gorgojo-Mart\u00ednez JJ, Mezquita-Raya P, Carretero-G\u00f3mez J et al (2022) Clinical recommendations to manage Gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus. J Clin Med Res 12. https:\/\/doi.org\/10.3390\/jcm12010145","DOI":"10.3390\/jcm12010145"},{"key":"4604_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/5584_2020_496","volume":"1307","author":"DB Maselli","year":"2021","unstructured":"Maselli DB, Camilleri M (2021) Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity. Adv Exp Med Biol 1307:171\u2013192","journal-title":"Adv Exp Med Biol"},{"key":"4604_CR34","doi-asserted-by":"publisher","first-page":"e250081","DOI":"10.1001\/jamanetworkopen.2025.0081","volume":"8","author":"Y-H Chen","year":"2025","unstructured":"Chen Y-H, Zink T, Chen Y-W et al (2025) Postoperative aspiration pneumonia among adults using GLP-1 receptor agonists. JAMA Netw Open 8:e250081","journal-title":"JAMA Netw Open"},{"key":"4604_CR35","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.thorsurg.2015.04.011","volume":"25","author":"KS Nason","year":"2015","unstructured":"Nason KS (2015) Acute intraoperative pulmonary aspiration. Thorac Surg Clin 25:301\u2013307","journal-title":"Thorac Surg Clin"},{"key":"4604_CR36","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1016\/j.arth.2017.01.004","volume":"32","author":"DD Bohl","year":"2017","unstructured":"Bohl DD, Saltzman BM, Sershon RA et al (2017) Incidence, risk factors, and clinical implications of pneumonia following total hip and knee arthroplasty. J Arthroplasty 32:1991\u20131995 .e1","journal-title":"J Arthroplasty"},{"key":"4604_CR37","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bjae.2020.07.003","volume":"20","author":"A Wynn-Hebden","year":"2020","unstructured":"Wynn-Hebden A, Bouch DC (2020) Anaesthesia for the obese patient. BJA Educ 20:388\u2013395","journal-title":"BJA Educ"},{"key":"4604_CR38","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1016\/j.arth.2023.05.071","volume":"38","author":"ML Magruder","year":"2023","unstructured":"Magruder ML, Yao VJH, Rodriguez AN et al (2023) Does semaglutide use decrease complications and costs following total knee. Arthroplasty? J Arthroplasty 38:2311\u20132315e1","journal-title":"Arthroplasty? J Arthroplasty"},{"key":"4604_CR39","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.arth.2023.07.017","volume":"39","author":"CK Mayfield","year":"2024","unstructured":"Mayfield CK, Mont MA, Lieberman JR, Heckmann ND (2024) Medical weight optimization for arthroplasty patients: A primer of emerging therapies for the joint arthroplasty surgeon. J Arthroplasty 39:38\u201343","journal-title":"J Arthroplasty"},{"key":"4604_CR40","doi-asserted-by":"publisher","unstructured":"Jacofsky D, Springer BD, Mont MA et al (2023) The impact of Glucagon-like peptide-1 (GLP-1) agonists on hip and knee arthroplasty and perioperative considerations. https:\/\/doi.org\/10.1016\/j.arth.2023.12.002. J Arthroplasty 0.","DOI":"10.1016\/j.arth.2023.12.002"},{"key":"4604_CR41","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2106\/JBJS.O.00430","volume":"98","author":"ER Wagner","year":"2016","unstructured":"Wagner ER, Kamath AF, Fruth KM et al (2016) Effect of body mass index on complications and reoperations after total hip arthroplasty. J Bone Joint Surg Am 98:169\u2013179","journal-title":"J Bone Joint Surg Am"},{"key":"4604_CR42","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.2106\/JBJS.16.00093","volume":"98","author":"ER Wagner","year":"2016","unstructured":"Wagner ER, Kamath AF, Fruth K et al (2016) Effect of body mass index on reoperation and complications after total knee arthroplasty. J Bone Joint Surg Am 98:2052\u20132060","journal-title":"J Bone Joint Surg Am"},{"key":"4604_CR43","doi-asserted-by":"publisher","first-page":"S249","DOI":"10.1016\/j.arth.2018.02.046","volume":"33","author":"S Yu","year":"2018","unstructured":"Yu S, Siow M, Odeh K et al (2018) Periarticular soft tissue envelope size and postoperative wound complications following total knee arthroplasty. J Arthroplasty 33:S249\u2013S252","journal-title":"J Arthroplasty"},{"key":"4604_CR44","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s42836-021-00102-7","volume":"4","author":"MW Seward","year":"2022","unstructured":"Seward MW, Chen AF (2022) Obesity, preoperative weight loss, and telemedicine before total joint arthroplasty: a review. Arthroplasty 4:2","journal-title":"Arthroplasty"},{"key":"4604_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/CORR.0000000000000615","volume":"477","author":"M Sloan","year":"2019","unstructured":"Sloan M, Sheth N, Lee G-C (2019) Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res 477:523\u2013532","journal-title":"Clin Orthop Relat Res"},{"key":"4604_CR46","first-page":"e27450","volume":"14","author":"VA Aggarwal","year":"2022","unstructured":"Aggarwal VA, Sambandam S, Wukich D (2022) The impact of obesity on total hip arthroplasty outcomes: A retrospective matched cohort study. Cureus 14:e27450","journal-title":"Cureus"},{"key":"4604_CR47","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.arth.2017.09.069","volume":"33","author":"LH Goodnough","year":"2018","unstructured":"Goodnough LH, Finlay AK, Huddleston JI 3rd et al (2018) Obesity is independently associated with early aseptic loosening in primary total hip arthroplasty. J Arthroplasty 33:882\u2013886","journal-title":"J Arthroplasty"},{"key":"4604_CR48","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.5435\/JAAOS-D-24-01284","volume":"33","author":"MF Levidy","year":"2025","unstructured":"Levidy MF, Vatsia S, Gohel N et al (2025) The effects of glucagon-like peptide-1 agonist therapy on risk of infection, fracture, and early revision in primary total joint arthroplasty. J Am Acad Orthop Surg 33:1213\u20131218","journal-title":"J Am Acad Orthop Surg"},{"key":"4604_CR49","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.knee.2025.08.007","volume":"57","author":"R Ranson","year":"2025","unstructured":"Ranson R, Parel PM, Kirkland J et al (2025) GLP-1 agonists are protective against postoperative complications following total knee arthroplasty. Knee 57:77\u201383","journal-title":"Knee"},{"key":"4604_CR50","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12891-020-03510-z","volume":"21","author":"CP Helito","year":"2020","unstructured":"Helito CP, Sobrado MF, Giglio PN et al (2020) The use of negative-pressure wound therapy after total knee arthroplasty is effective for reducing complications and the need for reintervention. BMC Musculoskelet Disord 21:490","journal-title":"BMC Musculoskelet Disord"},{"key":"4604_CR51","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.arth.2021.01.051","volume":"36","author":"MM Kheir","year":"2021","unstructured":"Kheir MM, Dilley JE, Ziemba-Davis M, Meneghini RM (2021) The AAHKS clinical research award: extended oral antibiotics prevent periprosthetic joint infection in High-Risk cases: 3855 patients with 1-Year Follow-Up. J Arthroplasty 36:S18\u2013S25","journal-title":"J Arthroplasty"},{"key":"4604_CR52","doi-asserted-by":"publisher","unstructured":"Magruder ML, Miskiewicz MJ, Rodriguez AN, Mont MA (2023) Semaglutide use prior to total hip arthroplasty results in fewer postoperative prosthetic joint infections and readmissions. https:\/\/doi.org\/10.1016\/j.arth.2023.12.023. J Arthroplasty 0.","DOI":"10.1016\/j.arth.2023.12.023"},{"key":"4604_CR53","doi-asserted-by":"publisher","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn W, De la Rosa A, Sacoto D et al (2022) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open 5:e2231982","journal-title":"JAMA Netw Open"},{"key":"4604_CR54","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325:1403\u20131413","journal-title":"JAMA"},{"key":"4604_CR55","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1056\/NEJMoa2403664","volume":"391","author":"H Bliddal","year":"2024","unstructured":"Bliddal H, Bays H, Czernichow S et al (2024) Once-weekly semaglutide in persons with obesity and knee osteoarthritis. N Engl J Med 391:1573\u20131583","journal-title":"N Engl J Med"}],"container-title":["European Journal of Orthopaedic Surgery & Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-025-04604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00590-025-04604-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00590-025-04604-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T06:47:09Z","timestamp":1765003629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00590-025-04604-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4604"],"URL":"https:\/\/doi.org\/10.1007\/s00590-025-04604-x","relation":{},"ISSN":["1432-1068"],"issn-type":[{"value":"1432-1068","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,6]]},"assertion":[{"value":"11 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"NDH - Royalties from a company or supplier: Corin U.S.A.; Paid consultant for a company or supplier: Intellijoint Surgical, MicroPort Orthopedics, Corin U.S.A, Zimmer; Stock or stock options in a company or supplier: Intellijoint Surgical; Board member\/committee appointments for a society: AAOS, AJRR, AAHKS, Knee SocietyJRL - Royalties from a company or supplier: DePuy: AJohnson &Johnson Company; Paid consultant for a company or supplier: DePuy: AJohnson &Johnson Company; Stock or stock options in a company or supplier: BD Surgiphor, Hip Innovations Technologies; Royalties, financial or material support from publishers: Saunders\/Mosby-Elsevier; Board member\/committee appointments for a society: AAOS, Hip Society, Musculoskeletal Transplant Foundation, Western Orthopaedic Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}